- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00111475
Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
A Dose-finding Study Evaluating the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Diagnosis of ITP according to American Society of Hematology (ASH) guidelines at least 3 months before enrollment
- Have completed at least 1 prior treatment for ITP
Two (including day -2) of the 3 platelet counts taken during the screening and pre-treatment periods must have fulfilled the following:
- less than 30 x 10^9/L for those subjects not receiving any ITP therapy,
- less than 50 x 10^9/L for those subjects receiving any ITP therapy
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Serum creatinine concentration ≤ 2 mg/dL (≤ 176.8 µmol/L)
- Adequate liver function, as evidenced by a serum bilirubin ≤ 1.5 times the laboratory normal range
- Hemoglobin greater than 10.0 g/dL
- Written informed consent
Exclusion Criteria:
- Considered a substantial risk for adverse outcomes because of a clinically important trend (as determined by the investigator) detected in the platelet counts during the screening period
- Any known history of bone marrow stem cell disorder
- Any active malignancy. If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years before randomization
- Documented diagnosis of arterial thrombosis (ie, stroke, transient ischemic attack, or myocardial infarction) in the previous year; history of venous thrombosis (ie, deep vein thrombosis, pulmonary embolism) and receiving anticoagulation therapy
- Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure [New York Heart Association (NYHA) greater than class II], uncontrolled hypertension [diastolic greater than 100 mmHg] or cardiac arrhythmia)
- Have 3 or more of the following predisposing factors for thromboembolic events: diabetes; smoker using oral contraceptives; hypercholesteremia (> 240 mg/dL); treatment for hypertension
- Known positive test for human immunodeficiency virus (HIV) infection or hepatitis C virus
- Received any treatment for ITP (except for a constant dose schedule of corticosteroids) within 4 weeks before the screening visit
- Received intravenous (IV) immunoglobulin (Ig) or WinRho within 2 weeks before the screening visit
- Received hematopoietic growth factors, including interleukin (IL)-11 (Neumega®) within 4 weeks before the screening visit
- Past or present participation in any study evaluating polyethylene glycol recombinant human magakaryopoiesis differentiating factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), or related platelet product
- Received any alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study
- Received any monoclonal antibody (eg, rituximab) within 16 weeks before the screening visit or anticipated use during the time of the proposed study
- Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA approved for any indication before the screening period
- Less than 2 months since major surgery (including laparoscopic splenectomy)
- Pregnant or breast feeding
- Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Part A: Romiplostim 0.2 µg/kg
Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
|
Administered by subcutaneous injection
Muut nimet:
|
Kokeellinen: Part A: Romiplostim 0.5 µg/kg
Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
|
Administered by subcutaneous injection
Muut nimet:
|
Kokeellinen: Part A: Romiplostim 1.0 µg/kg
Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.
|
Administered by subcutaneous injection
Muut nimet:
|
Kokeellinen: Part A: Romiplostim 3 µg/kg
Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
|
Administered by subcutaneous injection
Muut nimet:
|
Kokeellinen: Part A: Romiplostim 6 µg/kg
Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
|
Administered by subcutaneous injection
Muut nimet:
|
Kokeellinen: Part A: Romiplostim 10 µg/kg
Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
|
Administered by subcutaneous injection
Muut nimet:
|
Placebo Comparator: Part B: Placebo
Participants received placebo subcutaneously once a week for 6 weeks.
|
Annetaan ihonalaisena injektiona
|
Kokeellinen: Part B: Romiplostim 1.0 µg/kg
Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.
|
Administered by subcutaneous injection
Muut nimet:
|
Kokeellinen: Part B: Romiplostim 3.0 µg/kg
Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.
|
Administered by subcutaneous injection
Muut nimet:
|
Kokeellinen: Part B: Romiplostim 6.0 µg/kg
Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.
|
Administered by subcutaneous injection
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of Participants With Adverse Events
Aikaikkuna: From first dose of study drug through 8 weeks (Part A) or 6 weeks (Part B) after last dose of study drug; 78 days
|
From first dose of study drug through 8 weeks (Part A) or 6 weeks (Part B) after last dose of study drug; 78 days
|
|
Number of Participants With Anti-romiplostim or Anti-endogenous Thrombopoietin Neutralizing Antibodies
Aikaikkuna: Assessed on day 29 (Part A only), day 43 (Part B only), and day 78
|
The development of antibodies to romiplostim or to endogenous thrombopoietin (eTPO) was assessed using a neutralizing bioassay.
Participants positive for neutralizing antibodies at any of the assessments during the study are reported.
|
Assessed on day 29 (Part A only), day 43 (Part B only), and day 78
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of Participants Who Achieved Targeted Therapeutic Platelet Level in Part A
Aikaikkuna: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and between 50 to 450 x 10⁹ cells/L. Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders. |
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part A
Aikaikkuna: After first dose (day 1 to day 15 or 22), and after second dose (day 15 or 22 to day 78)
|
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
|
After first dose (day 1 to day 15 or 22), and after second dose (day 15 or 22 to day 78)
|
Number of Participants With a Peak Platelet Count ≥ 100 x 10⁹ Cells/L in Part A
Aikaikkuna: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
|
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Number of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part A
Aikaikkuna: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
|
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Peak Platelet Count After Each Dose in Part A
Aikaikkuna: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Platelet count data after the use of rescue medication were not included.
|
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Change From Baseline in Peak Platelet Count After Each Dose in Part A
Aikaikkuna: Baseline and after first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Platelet count data after the use of rescue medication were not included.
|
Baseline and after first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Time to Peak Platelet Count After Each Dose in Part A
Aikaikkuna: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Platelet count data after the use of rescue medication were not included.
|
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Duration Within the Targeted Therapeutic Platelet Range In Part A
Aikaikkuna: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and ≥ 50 and ≤ 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included. |
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
|
Percentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B
Aikaikkuna: Day 1 to day 78
|
Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 x 10⁹ cells/L and less than or equal to 450 x 10⁹ cells/L. Platelet count data after use of rescue medication were not included in the analysis. |
Day 1 to day 78
|
Percentage of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part B
Aikaikkuna: Day 1 to day 78
|
Platelet count data after administration of rescue medication were not included in the analysis.
Participants with no platelet count data were considered non-responders.
|
Day 1 to day 78
|
Percentage of Participants With a Peak Platelet Count of ≥ 100 x 10⁹ Cells/L in Part B
Aikaikkuna: Day 1 to day 78
|
Platelet count data after administration of rescue medication were not included in the analysis.
Participants with no platelet count data were considered non-responders.
|
Day 1 to day 78
|
Percentage of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part B
Aikaikkuna: Day 1 to day 78
|
Platelet count data after administration of rescue medication were not included in the analysis.
Participants with no platelet count data were considered non-responders.
|
Day 1 to day 78
|
Percentage of Participants With a Peak Platelet Count of > 500 x 10⁹ Cells/L in Part B
Aikaikkuna: Day 1 to day 78
|
Platelet count data after administration of rescue medication were not included in the analysis.
Participants with no platelet count data were considered non-responders.
|
Day 1 to day 78
|
Peak Platelet Count in Part B
Aikaikkuna: Day 1 to day 78
|
Platelet count data after administration of rescue medication were not included in the analysis.
|
Day 1 to day 78
|
Change From Baseline in Peak Platelet Count in Part B
Aikaikkuna: Baseline and day 1 to day 78
|
Platelet count data after administration of rescue medication were not included in the analysis.
|
Baseline and day 1 to day 78
|
Time to Peak Platelet Count in Part B
Aikaikkuna: Day 1 to day 78
|
Platelet count data after administration of rescue medication were not included in the analysis.
Time to peak platelet count was analyzed using the Kaplan-Meier method.
|
Day 1 to day 78
|
Duration Within the Targeted Therapeutic Platelet Range in Part B
Aikaikkuna: Day 1 to day 78
|
Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 × 10⁹ cells/L and less than or equal to 450 × 10⁹ cells/L. Platelet count data after administration of rescue medication were not included in the analysis. |
Day 1 to day 78
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017 Aug;102(8):1342-1351. doi: 10.3324/haematol.2016.161968. Epub 2017 Apr 14.
- Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006 Oct 19;355(16):1672-81. doi: 10.1056/NEJMoa054626. Erratum In: N Engl J Med. 2006 Nov 9;355(19):2054.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Immuunijärjestelmän sairaudet
- Autoimmuunisairaudet
- Hematologiset sairaudet
- Verenvuoto
- Hemorragiset häiriöt
- Veren hyytymishäiriöt
- Ihon ilmenemismuodot
- Trombosytopenia
- Verihiutaleiden häiriöt
- Tromboottiset mikroangiopatiat
- Purpura
- Purppura, trombosytopeeninen
- Purppura, trombosytopeeninen, idiopaattinen
Muut tutkimustunnusnumerot
- 20000137
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Plasebo
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyValmisMiespotilaat, joilla on tyypin II diabetes (T2DM)Saksa
-
National Institute on Drug Abuse (NIDA)ValmisKannabiksen käyttöYhdysvallat
-
Chiesi Farmaceutici S.p.A.ValmisAstmaYhdistynyt kuningaskunta
-
MedImmune LLCValmis
-
Eli Lilly and CompanyLopetettuNivelreumaYhdysvallat, Saksa, Taiwan, Ranska, Japani, Meksiko, Puola, Venäjän federaatio, Espanja, Kolumbia, Argentiina, Kreikka, Uusi Seelanti, Etelä-Afrikka, Australia, Korean tasavalta, Brasilia, Italia, Malesia
-
Alzheon Inc.National Institute on Aging (NIA)Aktiivinen, ei rekrytointiVarhainen Alzheimerin tautiYhdysvallat, Espanja, Kanada, Alankomaat, Tšekki, Yhdistynyt kuningaskunta, Ranska, Saksa, Islanti
-
GlaxoSmithKlineValmisLihavuus | Diabetes mellitus, tyyppi 2Yhdistynyt kuningaskunta
-
Chonbuk National University HospitalValmisToiminnallinen ummetusKorean tasavalta
-
Vitae Pharmaceuticals Inc., an Allergan affiliateValmis
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... ja muut yhteistyökumppanitValmisTerveYhdysvallat, Puerto Rico